TABLE 5.

Characterization of methotrexate nanoparticles using Eudragit S100.

Code	Drug:polymer	Particle size (nm)	Zeta potential (mV)	PDI	Amount encapsulated (mg/ml)	% Encapsulation efficiency
MSX1	1:5	114.6 ± 11.2	−2.92 ± 0.27	0.389 ± 0.22	0.78	39.26 ± 4.5
MSX2	1:5	109.7 ± 2.50	−2.36 ± 1.15	0.385 ± 0.006	0.73	36.81 ± 2.1
MSX3	1:5	135.1 ± 1.89	−1.59 ± 0.27	0.245 ± 0.016	0.65	32.68 ± 3.2
MSX4	1:10	171 ± 5.15	−0.10 ± 0.18	0.373 ± 0.045	1.14	63.02 ± 1.5
MSX5	1:10	165.7 ± 1.85	−0.163 ± 0.11	0.215 ± 0.010	1.228	61.42 ± 2.1
MSX6	1:10	185.9 ± 2.96	−3.54 ± 0.30	0.264 ± 0.014	1.01	50.7 ± 1.9
MSX7	1:15	231.9 ± 0.51	−5.06 ± 0.64	0.372 ± 0.018	1.31	65.89 ± 2.4
MSX8	1:15	174.6 ± 3.00	−5.64 ± 0.36	0.227 ± 0.017	1.4	70 ± 1.2
MSX9	1:15	202.6 ± 1.20	−2.28 ± 0.15	0.235 ± 0.008	1.38	69.19 ± 1.8
MSP1	1:5	776 ± 56	−0.23 ± 0.09	0.065 ± 0.08	1.40	70.18 ± 3.6
MSP2	1:5	492 ± 9.6	−11.5 ± 0.47	0.362 ± 0.04	1.20	60.01 ± 1.5
MSP3	1:5	1,190 ± 49	−0.161 ± 0.21	0.114 ± 0.13	0.98	49.36 ± 2.9
MSP4	1:10	981 ± 41.27	−1.97 ± 0.88	0.301 ± 0.45	1.62	81.45 ± 2.4
MSP5	1:10	872 ± 21.70	−0.841 ± 0.05	0.235 ± 0.08	1.39	69.51 ± 1.7
MSP6	1:10	1,336 ± 35.65	−1.05 ± 0.28	0.189 ± 0.46	1.08	54.47 ± 1.9
MSP7	1:15	1,241 ± 28.27	−0.67 ± 0.34	0.22 ± 0.11	1.82	91.31 ± 2.2
MSP8	1:15	1,118 ± 21.83	−0.355 ± 0.47	0.384 ± 0.35	1.51	75.82 ± 2.8
MSP9	1:15	1,528 ± 10.71	−0.796 ± 0.27	0.565 ± 0.33	1.20	60.08 ± 3.1

M, methotrexate; S, Eudragit S100; P, poly vinyl alcohol; X, Poloxamer-407.